Who are Hanall Biopharma's main competitors?

Named competitors: argenx (ARGX), UCB (private or unlisted). The cockpit's measured peer set (industry) also includes Lotus Pharmaceutical (1795.TW), Idorsia (IDIA.SW), Zhejiang Xianju Pharmaceutical (002332.SZ), Chongqing Genrix Biopharmaceutical (688443.SS), Phibro Animal Health (PAHC), Shanghai OPM Biosciences (688293.SS).

Is Hanall Biopharma expensive compared with its peers?

On ev / sales it trades at 11.2× against a peer median of 7.4×, 6th most expensive of 17 in its peer set.

How has Hanall Biopharma stock performed?

Over six months to 6 Nov 2026 the shares returned -24.7% against -10.9% for the median peer; over one year +2.6%.

← CockpitCompetitor Analysis › 009420.KS Hanall BiopharmaOpen in the cockpit ↗

Hanall Biopharma009420.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean biopharma developing autoimmune and eye-disease antibody drugs, including an FcRn inhibitor licensed to global partners.

Momentum weak 38

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$1.34B

US dollars, full cap

Free float

66%

of shares outstanding

$/day

$5.42M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-5.2 pp

WACC 7.5%

Hurdle

n/a

no reverse DCF

Next earnings

75 days

20 Jan 2027

Close · KRW₩35,700

1D-9.5%

1W-4.8%

1M-22.1%

3M-31.4%

6M-24.7%

YTD-18.4%

1Y+2.6%

ATR %7.0%

52w lowhigh51.1% off high

What Hanall Biopharma does

Korean biopharma developing autoimmune and eye-disease antibody drugs, including an FcRn inhibitor licensed to global partners.

Partners Immunovant and Harbour BioMed, not Hanall, run the late-stage trials for batoclimab, so Hanall relies on upfront payments, milestones and royalties from them while its Korean branded-generic drugs pay current costs.

Products and services

Batoclimab (FcRn inhibitor)
Ophthalmology drug pipeline
Branded generic drugs

Customers

Global pharma licensing partners (Harbour BioMed/I

Where it sits in the supply chain

Biotechnology
Autoimmune/ophthalmology antibody drugs
Global pharma licensing

What could go right

Batoclimab global approval/launch via partners
Milestone/royalty payments

What could go wrong

Clinical-trial/regulatory risk
Reliance on partner licensing milestones

Moat: narrow (IP / patents). Licensed FcRn-inhibitor antibody drug now in global late-stage trials via partners.

Headquarters: Seoul, South Korea · Founded: 1973 · Employees: 315

Named competitors

argenx ARGX
UCB private or unlisted

Hanall Biopharma at a glance

Size Hanall Biopharma (009420.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.34B, the 188th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩35,700 on 6 Nov 2026.

Performance Over six months the shares fell 24.7%, against -10.9% for the median peer and -24.5% for the South Korea market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 5.0% over the last twelve months (peer median +15.6%); the operating margin is 3.0% (peer median -5.9%).

Valuation It trades at 11.2× enterprise value to sales against a peer median of 7.4× (6th most expensive of 17).

Capital Return on invested capital runs 5.2 points below its cost of capital (7.5% WACC).

Next results Next results expected around 20 Jan 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Hanall Biopharma against the median of its 20 peers (local-currency closes).

Hanall Biopharma financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	₩162B	₩155B	₩139B	₩135B	₩110B
Revenue growth	—	+12%	+3%	+23%	—
Gross profit	n/a	₩79.1B	₩71.7B	₩73.7B	₩60.6B
EBITDA	n/a	₩1.94B	₩3.35B	₩4.99B	₩4.56B
Net income	-₩22.1B	-₩5.56B	-₩1.80B	₩3.51B	₩251M
Free cash flow	n/a	-₩3.29B	₩7.72B	₩27.2B	₩22.4B
Capital expenditure	n/a	₩14.1B	₩23.1B	₩9.20B	₩7.68B
Total debt	n/a	₩31.9B	₩1.45B	₩1.29B	₩1.31B

Quarterly statements and history in the cockpit →

Hanall Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Hanall Biopharma is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hanall Biopharma is the large dot.

Hanall Biopharma competitors and peer comparison

Head to head with its named competitors (009420.KS vs ARGX)
Company	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g
Hanall Biopharma 009420.KS	$1.34B	-25%	+5%	3%	11.2×	n/a
argenx SE Sponsored ADR ARGX	$57.5B	+19%	+71%	29%	10.0×	10.9%

How Hanall Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hanall Biopharma against its 20 peers (data as of 6 Nov 2026)
Measure	009420.KS	Peer median	Rank in peer set
1-month return	-22.1%	-6.4%	3rd lowest of 21
6-month return	-24.7%	-10.9%	7th lowest of 21
Distance from 52-week high	-51.1%	-36.2%	6th lowest of 21
Revenue growth (TTM)	+5.0%	+15.6%	6th lowest of 17
Operating margin	3.0%	-5.9%	7th highest of 17
EV / Sales	11.2×	7.4×	6th most expensive of 17
ROIC minus cost of capital	-5.2 pp	-5.9 pp	9th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Hanall Biopharma 009420.KS	South Korea	$1.34B	-25%	+5%	3%	11.2×	n/a	n/a
Lotus Pharmaceutical 1795.TW	Taiwan	$1.34B	-26%	+49%	24%	3.4×	-2.4%	+13.8%
Idorsia IDIA.SW	Switzerland	$1.34B	-5%	-5%	-70%	10.7×	n/a	n/a
Zhejiang Xianju Pharmaceutical 002332.SZ	China	$1.34B	+2%	+8%	11%	2.1×	0.3%	-1.3%
Chongqing Genrix Biopharmaceutical 688443.SS	China	$1.34B	-10%	+256%	-27%	10.0×	n/a	n/a
Phibro Animal Health PAHC	United States	$1.34B	-18%	+17%	13%	1.4×	-7.4%	+12.7%
Shanghai OPM Biosciences 688293.SS	China	$1.35B	+26%	+133%	11%	9.8×	26.1%	+23.1%
Tianjin Chase Sun Pharmaceutical 300026.SZ	China	$1.32B	-6%	-29%	3%	2.0×	8.5%	-5.3%
C.Q. Pharmaceutical 000950.SZ	China	$1.32B	-12%	-3%	1%	0.5×	n/a	n/a
LB Pharmaceuticals LBRX	United States	$1.36B	+31%	n/a	n/a	n/a	n/a	n/a
Sinopep-Allsino Bio Pharmaceutical 688076.SS	China	$1.31B	-7%	+14%	19%	5.0×	4.0%	+27.9%
Voronoi 310210.KS	South Korea	$1.31B	-66%	+24%	-1,947%	417.6×	n/a	n/a
Mabwell (Shanghai) Bioscience 2493.HK	Hong Kong	$1.37B	-32%	+21%	-127%	15.3×	n/a	n/a
Avalyn Pharma AVLN	United States	$1.29B	+7%	n/a	n/a	n/a	n/a	n/a
Innoviva INVA	United States	$1.38B	-17%	+18%	36%	2.4×	-15.4%	+3.9%
Ascentage Pharma Group International 6855.HK	Hong Kong	$1.39B	-33%	+70%	-220%	15.5×	n/a	n/a
PYC Therapeutics PYC.AX	Australia	$1.28B	+31%	n/a	n/a	n/a	n/a	n/a
Zhejiang Hisoar Pharmaceutical 002099.SZ	China	$1.39B	-9%	+9%	-13%	4.9×	n/a	n/a
D&D Pharmatech 347850.KS	South Korea	$1.28B	-49%	-71%	-1,368%	617.6×	n/a	n/a
GH Research GHRS	United States	$1.28B	-13%	n/a	n/a	n/a	n/a	n/a
Nektar Therapeutics NKTR	United States	$1.27B	-54%	-27%	-239%	13.3×	n/a	n/a

Questions

Who are Hanall Biopharma's main competitors?: Named competitors: argenx (ARGX), UCB (private or unlisted). The cockpit's measured peer set (industry) also includes Lotus Pharmaceutical (1795.TW), Idorsia (IDIA.SW), Zhejiang Xianju Pharmaceutical (002332.SZ), Chongqing Genrix Biopharmaceutical (688443.SS), Phibro Animal Health (PAHC), Shanghai OPM Biosciences (688293.SS).
Is Hanall Biopharma expensive compared with its peers?: On ev / sales it trades at 11.2× against a peer median of 7.4×, 6th most expensive of 17 in its peer set.
How has Hanall Biopharma stock performed?: Over six months to 6 Nov 2026 the shares returned -24.7% against -10.9% for the median peer; over one year +2.6%.